The life science industry is expected to be a major growth sector in Australia over the coming years with global pharmaceutical companies expanding their production capabilities across R&D, manufacturing, and distribution. This expansion, backed by Federal Government support is set to solidify Australia’s sovereign capability as the COVID-19 pandemic prompts a greater focus on this sector. So how will this impact occupier and investment activity growth within commercial property and where do we see this sector in ten years?
In this episode of Talking Property, Sass J-Baleh Head of Industrial & Logistics Research at CBRE sits down with Julie Phillips, CEO Biodiem Pty Ltd, Jack Walters Head of I&L Transactions at Charter Hall and Chris O’Brien Executive Director, Capital Markets, I&L at CBRE. Together, they take a closer a look at the Australian life sciences sector from pharmaceutical manufacturing and demand for life science assets, through to the types of investor groups showing more interest, major transactions and their predictions for industry growth over the next decade. This episode discusses findings from CBRE research report A New Era of Growth in Life Sciences. To read the full report, click here https://www.cbre.com.au/research-reports/a-new-era-of-growth-in-life-sciences

If you have any questions regarding this episode or property topics that you’d like CBRE to address in future episodes, please email us at [email protected].